Skip to main content

Table 1 demographic characteristics and imaging measurements per patient group

From: Visual assessment of posterior atrophy development of a MRI rating scale

  Controls AD Other dementias
N 38 60 20
Females 20 (53%)~ 30 (50%)~ 5 (25%)
Age (at diagnosis) 65.4 y (7) 66.4 y (10) 62.0 y (5)
Duration of symptoms 3.2 y (2) 4.7 y (5)
MMSEa 29 (20–30)/28 (2) 21 (9–30)/20 (4)* ~ 24 (17–30)/25 (4)*
MTA 0 (0–3)/0.4 (0.7) 1 (0–4)/1.3 (1.0)* 1 (0–4)/1.2 (1.0)*
GCA 0 (0–2)/0.2 (0.5) 1 (0–2)/1.1 (0.7)* ~ 1 (0–2)/0.7 (0.7)#
PA 0 (0–3)/0.6 (0.7) 0 (0–3)/1.6 (0.9)*† 0 (0–2)/0.8 (0.8)
  1. Data are presented as median (range)/mean (SD) or N (%)
  2. * p < 0. 01 compared to controls
  3. # p < 0. 05 compared to controls
  4. p < 0.01 compared to other dementias
  5. ~ p < 0. 05 compared to other dementias
  6. aMMSE available for 114 patients
  7. AD Alzheimer’s disease, N number of patients, MMSE mini-mental state examination, MTA medial temporal lobe atrophy, GCA global cortical atrophy, y years and PA posterior atrophy